| Bioactivity | CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay). | ||||||||||||
| Invitro | CPI-203 inhibits BRD4 in vitro and in cells, but does not affect BRD4 kinase activity in vitro[1]. CPI-203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 μM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, CPI-203 efficiently activates the cell death program in MCL cells[2]. | ||||||||||||
| Name | CPI-203 | ||||||||||||
| CAS | 1446144-04-2 | ||||||||||||
| Formula | C19H18ClN5OS | ||||||||||||
| Molar Mass | 399.90 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
CPI-203
CAS: 1446144-04-2 F: C19H18ClN5OS W: 399.90
CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.